Table 1 Correlation of BIRC5 expression levels with clinicopathological characteristics of HCC in the TMA cohort.
From: Development of a prognostic model for anoikis and identifies hub genes in hepatocellular carcinoma
Characteristic | Low expression of BIRC5 | High expression of BIRC5 | p |
|---|---|---|---|
Gender | 0.232 | ||
Male | 13 (68.4%) | 56 (81.2%) | |
Female | 6 (31.6%) | 13 (18.8%) | |
Age (year) | 0.219 | ||
≤ 60 | 8 (42.1%) | 40 (58.0%) | |
> 60 | 11 (57.9%) | 29 (42.0%) | |
Smoking history | 0.529 | ||
Not | 12 (63.2%) | 38 (55.1%) | |
Have | 7 (36.8%) | 31 (44.9%) | |
Drinking history | 0.255 | ||
Not | 15 (78.9%) | 45 (65.2%) | |
Have | 4 (21.1%) | 24 (34.8%) | |
Cirrhosis history | 0.204 | ||
Not | 3 (15.8%) | 21 (30.4%) | |
Have | 16 (84.2%) | 48 (69.6%) | |
T stage | 0.032 | ||
T1 and T2 | 19 (100.0%) | 55 (79.7%) | |
T3 and T4 | 0 (0.0%) | 14 (20.3%) | |
N stage | 0.453 | ||
N0 | 19 (100.0%) | 67 (97.1%) | |
N1 | 0 (0.0%) | 2 (2.9%) | |
Pathologic stage | 0.032 | ||
Stage I and II | 19 (100.0%) | 55 (79.7%) | |
Stage III and IV | 0 (0.0%) | 14 (20.3%) | |
AFP | 0.028 | ||
≤ 6.7 IU/ml | 11 (57.9%) | 21 (30.4%) | |
> 6.7 IU/ml | 8 (42.1%) | 48 (69.6%) | |
TB | 0.154 | ||
≤ 26 μmol/L | 16 (84.2%) | 65 (94.2%) | |
> 26 μmol/L | 3 (15.8%) | 4 (5.8%) | |
ALB | 0.569 | ||
< 40 g/L | 3 (15.8%) | 15 (21.7%) | |
≥ 40 g/L | 16 (84.2%) | 54 (78.3%) | |
Hepatits B virus infection | 0.673 | ||
No | 5 (26.3%) | 15 (21.7%) | |
Yes | 14 (73.7%) | 55 (78.3%) | |
HBV-DNA | 0.655 | ||
≤ 500 IU/ml | 8 (42.1%) | 34 (49.3%) | |
> 500 IU/ml | 4 (21.1%) | 17 (24.6%) | |
Missing | 7 (36.8%) | 18 (26.1%) | |
Tumor size | 4.50 ± 3.23 | 4.37 ± 2.99 | 0.873 |
Microvascular invasion | 0.241 | ||
Not | 10 (52.6%) | 26 (37.7%) | |
Have | 9 (47.4%) | 43 (62.3%) | |
Satellite nodules | 0.152 | ||
Not | 17 (89.5%) | 51 (73.9%) | |
Have | 2 (10.5%) | 18 (26.1%) | |
Liver capsule infiltration | 0.097 | ||
Not | 19 (100.0%) | 60 (87.0%) | |
Have | 0 (0.0%) | 9 (13.0%) | |
Portal vein invasion | 0.238 | ||
Not | 19 (100.0%) | 65 (94.2%) | |
Have | 0 (0.0%) | 4 (5.8%) | |
Portal vein embolus | 0.230 | ||
Not | 18 (94.7%) | 58 (84.1%) | |
Have | 1 (5.3%) | 11 (15.9%) | |
Histologic grade | 0.024 | ||
G1 and G2 | 17 (89.5%) | 43 (62.3%) | |
G3 and G4 | 2 (10.5%) | 26 (37.7%) |
